Exploring dendritic cell subtypes in cancer immunotherapy: unraveling the role of mature regulatory dendritic cells
Keywords:
Dendritic Cells, Immunotherapy, mregDC
Abstract
Dendritic cells (DCs) possess a specialized function in presenting antigens and play pivotal roles in both innate and adaptive immune responses. Their ability to cross-present antigens from tumor cells to naïve T cells is instrumental in generating specific T-cell-mediated antitumor responses, crucial for controlling tumor growth and preventing tumor cell dissemination. However, within a tumor immune microenvironment (TIME), the functions of DCs can be significantly compromised. This review focuses on the profile, function, and activation of DCs, leveraging recent studies that reveal insights into their phenotype acquisition, transcriptional state, and functional programs through single-cell RNA sequence (scRNA-seq) analysis. Additionally, the therapeutic potential of DC-mediated tumor antigen sensing in priming antitumor immunity is discussed.
Downloads
Download data is not yet available.
References
1. Steinman RM, Hawiger D, Liu K, Bonifaz L, Bonnyay D, Mahnke K, et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci. 2013;987:15–25. doi: 10.1111/j.1749-6632.2003.tb06029.x
2. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106:255–8. doi: 10.1016/s0092-8674(01)00449-4
3. Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186:1652–69. doi: 10.1016/j.cell.2023.03.006
4. Wherry J. T cell exhaustion. Nat Immunol. 2011;12:492–9. doi: 10.1038/ni.2035
5. Balan S, Saxena M, Bhardwaj N. Dendritic cell subsets and locations. Int Rev Cell Mol Biol. 2019;348:1–68. doi: 10.1016/bs.ircmb.2019.07.004
6. Prete AD, Salvi V, Soriani A, Laffranchi M. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. 2023;20:432–47. doi: 10.1038/s41423-023-00990-6
7. Villani A-C, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. 2017;356:4573. doi: 10.1126/science.aah4573
8. Boltjes A, Wijk F. Human dendritic cell functional specialization in steady-state and inflammation. Front Immunol. 2014;5:131. doi: 10.3389/fimmu.2014.00131
9. Dutertre C-A, Becht E, Irac SE, Khalilnezhad A, Narang V, Khalilnezhad S, et al. Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells. Immunity. 2019;51:573–89. doi: 10.1016/j.immuni.2019.08.008
10. Bourdely P, Anselmi G, Vaivode K, Ramos RN, Missolo-Koussou Y, Hidalgo S, et al. Transcriptional and functional analysis of CD1c+ human dendritic cells identifies a CD163+ subset priming CD8+CD103+ T cells. Immunity. 2020;53:335–52. doi: 10.1016/j.immuni.2020.06.002
11. Cytlak U, Resteu A, Pagan S, Green K, Milne P, Maisuria S, et al. Differential IRF8 transcription factor requirement defines two pathways of dendritic cell development in humans. Immunity. 2020;53:353–70. doi: 10.1016/j.immuni.2020.07.003
12. Gardner A, Ruffel B. Dendritic cells and cancer immunity. Trends Immunol. 2016;37:855–65. doi: 10.1016/j.it.2016.09.006
13. Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev. 2020;20:7–24. doi: 10.1038/s41577-019-0210-z
14. Yewdall AW, Drutman SB, Jinwala F, Bahjat KS, Bhardwaj N, et al. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One. 2010;5:e11144. doi: 10.1371/journal.pone.0011144
15. Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med. 1998;188:2163–73. doi: 10.1084/jem.188.11.2163
16. Chaplin D. Overview of the immune response. J Allergy Clin Immunol. 2010;125:3–23. doi: 10.1016/j.jaci.2009.12.980
17. Datsi A, Sorg RV. Dendritic cell vaccination of glioblastoma: road to success or dead end. Front Immunol. 2021;12:770390. doi: 10.3389/fimmu.2021.770390
18. Fucikova J, Palova-Jelinkova L, Bartunkova J, Spisek R, et al. Induction of tolerance and immunity by dendritic cells: mechanisms and clinical applications. Front Immunol. 2019;10:2393. doi: 10.3389/fimmu.2019.02393
19. Merad M, Sathe P, Helft J, Miller J, Mortha A, et al. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563–604. doi: 10.1146/annurev-immunol-020711-074950
20. Guilliams M, Dutertre C-A, Scott CL, McGovern N, Sichien D, Chakarov S, et al. Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity. 2016;45:669–84. doi: 10.1016/j.immuni.2016.08.015
21. Hu X, Jiang C, Gao Y, Xue X. Human dendritic cell subsets in the glioblastoma-associated microenvironment. J Neuroimmunol. 2023 Oct 15:383:578147. doi: 10.1016/j.jneuroim.2023.578147
22. Maier B, Leader AM, Chen ST, Tung N, Chang C, LeBerichel J, et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature. 2020;580:257–62. doi: 10.1038/s41586-020-2134-y
23. Ma W, Lee J, Backenroth D, Zhou YJ, Bush E, Sims P, et al. Single cell RNA-Seq reveals pre-cDCs fate determined by transcription factor combinatorial dose. BMC Mol Cell Biol. 2019;20:20. doi: 10.1186/s12860-019-0199-y
24. Mrdjen D, Pavlovic A, Hartmann FJ, Schreiner B, Utz SG, Leung BP, et al. High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity. 2018;48:380–95 doi: 10.1016/j.immuni.2018.01.011
25. Li Y, Jeong J, Song W. Molecular characteristics and distribution of adult human corneal immune cell types. Front Immunol. 2022:13:798346. doi: 10.3389/fimmu.2022.798346
26. Liu Z, Wang H, Li Z, Dress RJ, Zhu Y, Zhang S, et al. Dendritic cell type 3 arises from Ly6C+ monocyte-dendritic cell progenitors. Immunity. 2023 Aug 8;56:1761–77.e6. doi: 10.1016/j.immuni.2023.07.001
27. Antunes ARP, Scheyltjens I, Lodi F, Messiaen J, Antoranz A, Duerinck J, et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat Neurosci. 2021;24:595–610. doi: 10.1038/s41593-020-00789-y
28. Lee AH, Sun L, Mochizuki AY, Reynoso JG, Orpilla J, Chow F, et al. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun. 2021 Nov 26;12:6938. doi: 10.1038/s41467-021-26940-2
29. Smalley I, Chen Z, Phadke M, Li J, Yu X, Wyatt C, et al. Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases. Clin Cancer Res. 2021;27:4109–25. doi: 10.1158/1078-0432.CCR-21-1694
30. Zou Y, Ye F, Kong Y, Hu X, Deng X, Xie J, et al. The single-cell landscape of intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast cancer. Adv Sci (Weinh). 2023;10:e2203699. doi: 10.1002/advs.202203699
31. Wei B, Liu Z, Fan Y, Wang S, Dong C, Rao W, et al. Analysis of cellular heterogeneity in immune microenvironment of primary central nervous system lymphoma by single-cell sequencing. Front Oncol. 2021 Oct 4:11:683007. doi: 10.3389/fonc.2021.683007
32. Minohara K, Imai M, Matoba T, Wing JB, Shime H, Odanaka M, et al. Mature dendritic cells enriched in regulatory molecules may control regulatory T cells and the prognosis of head and neck cancer. Cancer Sci. 2023;114:1256–69. doi: 10.1111/cas.15698
33. Zhang Q, He Y, Luo N, Patel SJ, Han Y, Gao R, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. cell. 2019;179:829–45. doi: 10.1016/j.cell.2019.10.003
34. Zilionis R, Engblom C, Pfirschke C, Savova V, Zemmour D, Saatcioglu HD, et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity. 2019;50:1317–34. doi: 10.1016/j.immuni.2019.03.009
35. Ardouin L, Luche H, Chelbi R, Carpentier S, Shawket A, Sanchis FM, et al. Broad and largely concordant molecular changes characterize tolerogenic and immunogenic dendritic cell maturation in thymus and periphery. Immunity. 2016;45:305–18. doi: 10.1016/j.immuni.2016.07.019
36. Miller JC, Brown BD, Shay T, Gautier EL, Jojic V, Cohain A, et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat Immunol. 2012;13:888–99. doi: 10.1038/ni.2370
37. Nirschl CJ, Suárez-Fariñas M, Izar B, Prakadan S, Dannenfelser R, Tirosh I, et al. IFNγ-Dependent tissue-immune homeostasis is co-opted in the tumor microenvironment. Cell. 2017;170:127–41. doi: 10.1016/j.cell.2017.06.016
38. Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, et al. Immune landscape of viral- and carcinogen-driven head and neck cancer. Immunity. 2020;52:183–99. doi: 10.1016/j.immuni.2019.11.014
39. Ji AL, Rubin AJ, Thrane K, Jiang S, Reynolds DL, Meyers RM, et al. Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma. Cell. 2020;182:497–514. doi: 10.1016/j.cell.2020.05.039
40. Qian J, Olbrecht S, Boeckx B, Vos H, Laoui D, Etlioglu E, et al. A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. Cell Res. 2020;30:745–62. doi: 10.1038/s41422-020-0355-0
41. Gerhard GM, Bill R, Messemaker M, Klein AM, Pittet MJ, et al. Tumor-infiltrating dendritic cell states are conserved across solid human cancers. J Exp Med. 2021;218. doi: 10.1084/jem.20200264
42. Ginhoux F, Guilliams M, Merad M. Expanding dendritic cell nomenclature in the single-cell era. Nat Rev Immunol. 2022;22:67–8. doi: 10.1038/s41577-022-00675-7
43. Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O’Brien SA, He Y, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020;181:442–59. doi: 10.1016/j.cell.2020.03.048
44. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10. doi: 10.1016/j.immuni.2013.07.012
45. Duraiswamy J, Turrini R, Minasyan A, Barras D, Crespo I, Grimm AJ, et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell. 2021;39:1623–42. doi: 10.1016/j.ccell.2021.10.008
46. Magen A, Hamon P, Fiaschi N, Soong BY, Park MD, Mattiuz R, et al. Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat Med. 2023;29:1389–99. doi: 10.1038/s41591-023-02345-0
47. Lee Barrett R, Puré E. Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy. Ellife. 2020;9:e57243. doi: 10.7554/eLife.57243
48. Caligiuri G, Tuveson DA. Activated fibroblasts in cancer: perspectives and challenges. Cancer Cell. 2023;41:434–49. doi: 10.1016/j.ccell.2023.02.015
49. Pittet MJ, Di Pilato M, Garris C, Mempel TR. Dendritic cells as shepherds of T cell immunity in cancer. Immunity. 2023;56:2218–30. doi: 10.1016/j.immuni.2023.08.014
50. Mani V, Bromley SK, Äijö T, Mora-Buch R, Carrizos E, Warner RD, Chasse AY, et al. Migratory DCs activate TGF-β to precondition naïve CD8+ T cells for tissue-resident memory fate. Science. 2019;366:6462. doi: 10.1126/science.aav5728
51. Matyszak MK, Perry VH. The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. Neuroscience. 1996;74:599–608. doi: 10.1016/0306-4522(96)00160-1
52. McMenamin. Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. J Comp Neurol. 1999;405:553–62. PMID:10098945
53. Engelhardt B, Vajkoczy P, Weller RO. The movers and shapers in immune privilege of the CNS. Nat Immunol. 2017;18:123–31. doi: 10.1038/ni.3666
54. D’Agostino PM, Gottfried-Blackmore A, Anandasabapathy N, Bulloch K, et al. Brain dendritic cells: biology and pathology. Acta Neuropathol. 2012;124:599–614. doi: 10.1007/s00401-012-1018-0
55. Li X, Lyu J, Li R, Jain V, Shen Y, del Águila Á, et al. Single-cell transcriptomic analysis of the immune cell landscape in the aged mouse brain after ischemic stroke. Journal of Neuroinflammation. 2022;19:83 doi: 10.1186/s12974-022-02447-5
56. Cheng S, Liu L, Wang D, Li Y, Li S, Yuan J, et al. Upregulation of the ZNF148/PTX3 axis promotes malignant transformation of dendritic cells in glioma stem-like cells microenvironment. CNS Neurosci Ther. 2023;29:2690–704. doi: 10.1111/cns.14213
57. Dey M, Chang AL, Miska J, Wainwright DA, Ahmed AU, Balyasnikova IV, et al. Dendritic cell based vaccines that utilize myeloid rather than plasmacytoid cells offer a superior survival advantage in malignant glioma. J Immunol. 2015;195:367–76. doi: 10.4049/jimmunol.1401607
58. Li H, Zhu S, Zhou J, Chen D, Liu J, Wu Z, et al. Tertiary lymphoid structure raises survival and immunotherapy in HPV- HNSCC. J Dent Res. 2023;102:678–88. doi: 10.1177/00220345231151685
59. Ladányi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother. 2007;56:1459–69. doi: 10.1007/s00262-007-0286-3
60. Nishimura J, Tanaka H, Yamakoshi Y, Hiramatsu S, Tamura T, Toyokawa T, et al. Impact of tumor-infiltrating LAMP-3 dendritic cells on the prognosis of esophageal squamous cell carcinoma. Esophagus. 2019;16:333–44. doi: 10.1007/s10388-019-00669-w
61. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549–55. doi: 10.1038/s41586-019-1922-8
62. Lu H, Lou H, Wengert G, Paudel R, Patel N, Desai S, et al. Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer. Cell Rep Med. 2023;4:101092. doi: 10.1016/j.xcrm.2023.101092
63. Patil NS, Nabet BY, Müller S, Koeppen H, Zou W, Giltnane J, et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell. 2022;40:289–300. doi: 10.1016/j.ccell.2022.02.002
64. Vanhersecke L, Brunet M, Guégan J-P, Rey C, Bougouin A, Cousin S, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021;2:794–802. doi: 10.1038/s43018-021-00232-6
65. Hooren L, Vaccaro A, Ramachandran M, Vazaios K, Libard S, Van de Walle T, et al. Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. Nat Commun. 2021;12:4127 doi: 10.1038/s41467-021-24347-7
66. Mauldin IS, Jo J, Wages N, Yogendran LV, Mahmutovic A, Young SJ, et al. Proliferating CD8+ T cell infiltrates are associated with improved survival in glioblastoma. Cells. 2021;10:3378. doi: 10.3390/cells10123378
67. Thumkeo D, Punyawatthananukool S, Prasongtanakij S, Matsuura R, Arima K, Nie H, et al. PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment. Cell Rep. 2022;39:110914. doi: 10.1016/j.celrep.2022.110914
68. Movassagh M, Spatz A, Davoust J, Lebecque S, Romero P, Pittet M, Rimoldi D, et al. Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res. 2004;64:2192–8. doi: 10.1158/0008-5472.can-03-2969
69. Chen C-Y, Ueha S, Ishiwata Y, Shichino S, Yokochi S, Yang D, et al. Combining an alarmin HMGN1 peptide with PD-L1 blockade results in robust antitumor effects with a concomitant increase of stem-like/progenitor exhausted CD8+ T cells. Cancer Immunol Res. 2021;9:1214–28. doi: 10.1158/2326-6066.CIR-21-0265
70. Wu S-Y, Zhang S-W, Ma D, Xiao Y, Liu Y, Chen Li, et al. CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. Med. 2023;4:373–93. doi: 10.1016/j.medj.2023.04.008
71. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–21. doi: 10.1038/s41423-020-0488-6
72. Nakai N, Asai J, Ueda E, Takenaka H, Katoh N, Kishimoto S. Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells. J Dermatol. 2006;33:462–72. doi: 10.1111/j.1346-8138.2006.00110.x
73. Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, Kiyohara Y, et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep. 2012;28:1131–8. doi: 10.3892/or.2012.1956
74. Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. Clin Cancer Res. 2021;27:4574–86. doi: 10.1158/1078-0432.CCR-21-1047
75. Oh SA, Wu D-C, Cheung J, Navarro A, Xiong H, Cubas R. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer. 2020;1:681–91. doi: 10.1038/s43018-020-0075-x
76. Siesjö P, Visse E, Sjögren HO. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J Immunother Emphasis Tumor Immunol. 1996;19:334–45. PMID:8941873
77. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg. 1999;90:1115–24. doi: 10.3171/jns.1999.90.6.1115
78. Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2023;9:112–121 doi: 10.1001/jamaoncol.2022.5370
79. Vieira PL, De Jong EC, Wierenga EA, Kapsenberg ML, Kaliński P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol. 2000;164:4507–12. doi: 10.4049/jimmunol.164.9.4507
80. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 1999;59:4035–41. PMID:10463604
81. Belmans J, Van Woensel M, Creyns B, Dejaegher J, Bullens DM, Van Gool SW, et al. Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival. Sci Rep. 2017;13902. doi: 10.1038/s41598-017-12584-0
82. Jouanneau E, Poujol D, Gulia S, Le Mercier I, Blay JY, Belin MF, Puisieux I. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model. Cancer Immunol Immunother. 2006;55:254–67. doi: 10.1007/s00262-005-0040-7
2. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106:255–8. doi: 10.1016/s0092-8674(01)00449-4
3. Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186:1652–69. doi: 10.1016/j.cell.2023.03.006
4. Wherry J. T cell exhaustion. Nat Immunol. 2011;12:492–9. doi: 10.1038/ni.2035
5. Balan S, Saxena M, Bhardwaj N. Dendritic cell subsets and locations. Int Rev Cell Mol Biol. 2019;348:1–68. doi: 10.1016/bs.ircmb.2019.07.004
6. Prete AD, Salvi V, Soriani A, Laffranchi M. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. 2023;20:432–47. doi: 10.1038/s41423-023-00990-6
7. Villani A-C, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. 2017;356:4573. doi: 10.1126/science.aah4573
8. Boltjes A, Wijk F. Human dendritic cell functional specialization in steady-state and inflammation. Front Immunol. 2014;5:131. doi: 10.3389/fimmu.2014.00131
9. Dutertre C-A, Becht E, Irac SE, Khalilnezhad A, Narang V, Khalilnezhad S, et al. Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells. Immunity. 2019;51:573–89. doi: 10.1016/j.immuni.2019.08.008
10. Bourdely P, Anselmi G, Vaivode K, Ramos RN, Missolo-Koussou Y, Hidalgo S, et al. Transcriptional and functional analysis of CD1c+ human dendritic cells identifies a CD163+ subset priming CD8+CD103+ T cells. Immunity. 2020;53:335–52. doi: 10.1016/j.immuni.2020.06.002
11. Cytlak U, Resteu A, Pagan S, Green K, Milne P, Maisuria S, et al. Differential IRF8 transcription factor requirement defines two pathways of dendritic cell development in humans. Immunity. 2020;53:353–70. doi: 10.1016/j.immuni.2020.07.003
12. Gardner A, Ruffel B. Dendritic cells and cancer immunity. Trends Immunol. 2016;37:855–65. doi: 10.1016/j.it.2016.09.006
13. Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev. 2020;20:7–24. doi: 10.1038/s41577-019-0210-z
14. Yewdall AW, Drutman SB, Jinwala F, Bahjat KS, Bhardwaj N, et al. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One. 2010;5:e11144. doi: 10.1371/journal.pone.0011144
15. Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med. 1998;188:2163–73. doi: 10.1084/jem.188.11.2163
16. Chaplin D. Overview of the immune response. J Allergy Clin Immunol. 2010;125:3–23. doi: 10.1016/j.jaci.2009.12.980
17. Datsi A, Sorg RV. Dendritic cell vaccination of glioblastoma: road to success or dead end. Front Immunol. 2021;12:770390. doi: 10.3389/fimmu.2021.770390
18. Fucikova J, Palova-Jelinkova L, Bartunkova J, Spisek R, et al. Induction of tolerance and immunity by dendritic cells: mechanisms and clinical applications. Front Immunol. 2019;10:2393. doi: 10.3389/fimmu.2019.02393
19. Merad M, Sathe P, Helft J, Miller J, Mortha A, et al. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563–604. doi: 10.1146/annurev-immunol-020711-074950
20. Guilliams M, Dutertre C-A, Scott CL, McGovern N, Sichien D, Chakarov S, et al. Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity. 2016;45:669–84. doi: 10.1016/j.immuni.2016.08.015
21. Hu X, Jiang C, Gao Y, Xue X. Human dendritic cell subsets in the glioblastoma-associated microenvironment. J Neuroimmunol. 2023 Oct 15:383:578147. doi: 10.1016/j.jneuroim.2023.578147
22. Maier B, Leader AM, Chen ST, Tung N, Chang C, LeBerichel J, et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature. 2020;580:257–62. doi: 10.1038/s41586-020-2134-y
23. Ma W, Lee J, Backenroth D, Zhou YJ, Bush E, Sims P, et al. Single cell RNA-Seq reveals pre-cDCs fate determined by transcription factor combinatorial dose. BMC Mol Cell Biol. 2019;20:20. doi: 10.1186/s12860-019-0199-y
24. Mrdjen D, Pavlovic A, Hartmann FJ, Schreiner B, Utz SG, Leung BP, et al. High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity. 2018;48:380–95 doi: 10.1016/j.immuni.2018.01.011
25. Li Y, Jeong J, Song W. Molecular characteristics and distribution of adult human corneal immune cell types. Front Immunol. 2022:13:798346. doi: 10.3389/fimmu.2022.798346
26. Liu Z, Wang H, Li Z, Dress RJ, Zhu Y, Zhang S, et al. Dendritic cell type 3 arises from Ly6C+ monocyte-dendritic cell progenitors. Immunity. 2023 Aug 8;56:1761–77.e6. doi: 10.1016/j.immuni.2023.07.001
27. Antunes ARP, Scheyltjens I, Lodi F, Messiaen J, Antoranz A, Duerinck J, et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat Neurosci. 2021;24:595–610. doi: 10.1038/s41593-020-00789-y
28. Lee AH, Sun L, Mochizuki AY, Reynoso JG, Orpilla J, Chow F, et al. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun. 2021 Nov 26;12:6938. doi: 10.1038/s41467-021-26940-2
29. Smalley I, Chen Z, Phadke M, Li J, Yu X, Wyatt C, et al. Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases. Clin Cancer Res. 2021;27:4109–25. doi: 10.1158/1078-0432.CCR-21-1694
30. Zou Y, Ye F, Kong Y, Hu X, Deng X, Xie J, et al. The single-cell landscape of intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast cancer. Adv Sci (Weinh). 2023;10:e2203699. doi: 10.1002/advs.202203699
31. Wei B, Liu Z, Fan Y, Wang S, Dong C, Rao W, et al. Analysis of cellular heterogeneity in immune microenvironment of primary central nervous system lymphoma by single-cell sequencing. Front Oncol. 2021 Oct 4:11:683007. doi: 10.3389/fonc.2021.683007
32. Minohara K, Imai M, Matoba T, Wing JB, Shime H, Odanaka M, et al. Mature dendritic cells enriched in regulatory molecules may control regulatory T cells and the prognosis of head and neck cancer. Cancer Sci. 2023;114:1256–69. doi: 10.1111/cas.15698
33. Zhang Q, He Y, Luo N, Patel SJ, Han Y, Gao R, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. cell. 2019;179:829–45. doi: 10.1016/j.cell.2019.10.003
34. Zilionis R, Engblom C, Pfirschke C, Savova V, Zemmour D, Saatcioglu HD, et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity. 2019;50:1317–34. doi: 10.1016/j.immuni.2019.03.009
35. Ardouin L, Luche H, Chelbi R, Carpentier S, Shawket A, Sanchis FM, et al. Broad and largely concordant molecular changes characterize tolerogenic and immunogenic dendritic cell maturation in thymus and periphery. Immunity. 2016;45:305–18. doi: 10.1016/j.immuni.2016.07.019
36. Miller JC, Brown BD, Shay T, Gautier EL, Jojic V, Cohain A, et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat Immunol. 2012;13:888–99. doi: 10.1038/ni.2370
37. Nirschl CJ, Suárez-Fariñas M, Izar B, Prakadan S, Dannenfelser R, Tirosh I, et al. IFNγ-Dependent tissue-immune homeostasis is co-opted in the tumor microenvironment. Cell. 2017;170:127–41. doi: 10.1016/j.cell.2017.06.016
38. Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, et al. Immune landscape of viral- and carcinogen-driven head and neck cancer. Immunity. 2020;52:183–99. doi: 10.1016/j.immuni.2019.11.014
39. Ji AL, Rubin AJ, Thrane K, Jiang S, Reynolds DL, Meyers RM, et al. Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma. Cell. 2020;182:497–514. doi: 10.1016/j.cell.2020.05.039
40. Qian J, Olbrecht S, Boeckx B, Vos H, Laoui D, Etlioglu E, et al. A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. Cell Res. 2020;30:745–62. doi: 10.1038/s41422-020-0355-0
41. Gerhard GM, Bill R, Messemaker M, Klein AM, Pittet MJ, et al. Tumor-infiltrating dendritic cell states are conserved across solid human cancers. J Exp Med. 2021;218. doi: 10.1084/jem.20200264
42. Ginhoux F, Guilliams M, Merad M. Expanding dendritic cell nomenclature in the single-cell era. Nat Rev Immunol. 2022;22:67–8. doi: 10.1038/s41577-022-00675-7
43. Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O’Brien SA, He Y, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020;181:442–59. doi: 10.1016/j.cell.2020.03.048
44. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10. doi: 10.1016/j.immuni.2013.07.012
45. Duraiswamy J, Turrini R, Minasyan A, Barras D, Crespo I, Grimm AJ, et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell. 2021;39:1623–42. doi: 10.1016/j.ccell.2021.10.008
46. Magen A, Hamon P, Fiaschi N, Soong BY, Park MD, Mattiuz R, et al. Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat Med. 2023;29:1389–99. doi: 10.1038/s41591-023-02345-0
47. Lee Barrett R, Puré E. Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy. Ellife. 2020;9:e57243. doi: 10.7554/eLife.57243
48. Caligiuri G, Tuveson DA. Activated fibroblasts in cancer: perspectives and challenges. Cancer Cell. 2023;41:434–49. doi: 10.1016/j.ccell.2023.02.015
49. Pittet MJ, Di Pilato M, Garris C, Mempel TR. Dendritic cells as shepherds of T cell immunity in cancer. Immunity. 2023;56:2218–30. doi: 10.1016/j.immuni.2023.08.014
50. Mani V, Bromley SK, Äijö T, Mora-Buch R, Carrizos E, Warner RD, Chasse AY, et al. Migratory DCs activate TGF-β to precondition naïve CD8+ T cells for tissue-resident memory fate. Science. 2019;366:6462. doi: 10.1126/science.aav5728
51. Matyszak MK, Perry VH. The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. Neuroscience. 1996;74:599–608. doi: 10.1016/0306-4522(96)00160-1
52. McMenamin. Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. J Comp Neurol. 1999;405:553–62. PMID:10098945
53. Engelhardt B, Vajkoczy P, Weller RO. The movers and shapers in immune privilege of the CNS. Nat Immunol. 2017;18:123–31. doi: 10.1038/ni.3666
54. D’Agostino PM, Gottfried-Blackmore A, Anandasabapathy N, Bulloch K, et al. Brain dendritic cells: biology and pathology. Acta Neuropathol. 2012;124:599–614. doi: 10.1007/s00401-012-1018-0
55. Li X, Lyu J, Li R, Jain V, Shen Y, del Águila Á, et al. Single-cell transcriptomic analysis of the immune cell landscape in the aged mouse brain after ischemic stroke. Journal of Neuroinflammation. 2022;19:83 doi: 10.1186/s12974-022-02447-5
56. Cheng S, Liu L, Wang D, Li Y, Li S, Yuan J, et al. Upregulation of the ZNF148/PTX3 axis promotes malignant transformation of dendritic cells in glioma stem-like cells microenvironment. CNS Neurosci Ther. 2023;29:2690–704. doi: 10.1111/cns.14213
57. Dey M, Chang AL, Miska J, Wainwright DA, Ahmed AU, Balyasnikova IV, et al. Dendritic cell based vaccines that utilize myeloid rather than plasmacytoid cells offer a superior survival advantage in malignant glioma. J Immunol. 2015;195:367–76. doi: 10.4049/jimmunol.1401607
58. Li H, Zhu S, Zhou J, Chen D, Liu J, Wu Z, et al. Tertiary lymphoid structure raises survival and immunotherapy in HPV- HNSCC. J Dent Res. 2023;102:678–88. doi: 10.1177/00220345231151685
59. Ladányi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother. 2007;56:1459–69. doi: 10.1007/s00262-007-0286-3
60. Nishimura J, Tanaka H, Yamakoshi Y, Hiramatsu S, Tamura T, Toyokawa T, et al. Impact of tumor-infiltrating LAMP-3 dendritic cells on the prognosis of esophageal squamous cell carcinoma. Esophagus. 2019;16:333–44. doi: 10.1007/s10388-019-00669-w
61. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549–55. doi: 10.1038/s41586-019-1922-8
62. Lu H, Lou H, Wengert G, Paudel R, Patel N, Desai S, et al. Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer. Cell Rep Med. 2023;4:101092. doi: 10.1016/j.xcrm.2023.101092
63. Patil NS, Nabet BY, Müller S, Koeppen H, Zou W, Giltnane J, et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell. 2022;40:289–300. doi: 10.1016/j.ccell.2022.02.002
64. Vanhersecke L, Brunet M, Guégan J-P, Rey C, Bougouin A, Cousin S, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021;2:794–802. doi: 10.1038/s43018-021-00232-6
65. Hooren L, Vaccaro A, Ramachandran M, Vazaios K, Libard S, Van de Walle T, et al. Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. Nat Commun. 2021;12:4127 doi: 10.1038/s41467-021-24347-7
66. Mauldin IS, Jo J, Wages N, Yogendran LV, Mahmutovic A, Young SJ, et al. Proliferating CD8+ T cell infiltrates are associated with improved survival in glioblastoma. Cells. 2021;10:3378. doi: 10.3390/cells10123378
67. Thumkeo D, Punyawatthananukool S, Prasongtanakij S, Matsuura R, Arima K, Nie H, et al. PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment. Cell Rep. 2022;39:110914. doi: 10.1016/j.celrep.2022.110914
68. Movassagh M, Spatz A, Davoust J, Lebecque S, Romero P, Pittet M, Rimoldi D, et al. Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res. 2004;64:2192–8. doi: 10.1158/0008-5472.can-03-2969
69. Chen C-Y, Ueha S, Ishiwata Y, Shichino S, Yokochi S, Yang D, et al. Combining an alarmin HMGN1 peptide with PD-L1 blockade results in robust antitumor effects with a concomitant increase of stem-like/progenitor exhausted CD8+ T cells. Cancer Immunol Res. 2021;9:1214–28. doi: 10.1158/2326-6066.CIR-21-0265
70. Wu S-Y, Zhang S-W, Ma D, Xiao Y, Liu Y, Chen Li, et al. CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. Med. 2023;4:373–93. doi: 10.1016/j.medj.2023.04.008
71. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–21. doi: 10.1038/s41423-020-0488-6
72. Nakai N, Asai J, Ueda E, Takenaka H, Katoh N, Kishimoto S. Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells. J Dermatol. 2006;33:462–72. doi: 10.1111/j.1346-8138.2006.00110.x
73. Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, Kiyohara Y, et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep. 2012;28:1131–8. doi: 10.3892/or.2012.1956
74. Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. Clin Cancer Res. 2021;27:4574–86. doi: 10.1158/1078-0432.CCR-21-1047
75. Oh SA, Wu D-C, Cheung J, Navarro A, Xiong H, Cubas R. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer. 2020;1:681–91. doi: 10.1038/s43018-020-0075-x
76. Siesjö P, Visse E, Sjögren HO. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J Immunother Emphasis Tumor Immunol. 1996;19:334–45. PMID:8941873
77. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg. 1999;90:1115–24. doi: 10.3171/jns.1999.90.6.1115
78. Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2023;9:112–121 doi: 10.1001/jamaoncol.2022.5370
79. Vieira PL, De Jong EC, Wierenga EA, Kapsenberg ML, Kaliński P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol. 2000;164:4507–12. doi: 10.4049/jimmunol.164.9.4507
80. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 1999;59:4035–41. PMID:10463604
81. Belmans J, Van Woensel M, Creyns B, Dejaegher J, Bullens DM, Van Gool SW, et al. Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival. Sci Rep. 2017;13902. doi: 10.1038/s41598-017-12584-0
82. Jouanneau E, Poujol D, Gulia S, Le Mercier I, Blay JY, Belin MF, Puisieux I. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model. Cancer Immunol Immunother. 2006;55:254–67. doi: 10.1007/s00262-005-0040-7
Published
2024-04-12
How to Cite
Badillo O., Helfridsson L., Niemi J., & Hellström M. (2024). Exploring dendritic cell subtypes in cancer immunotherapy: unraveling the role of mature regulatory dendritic cells. Upsala Journal of Medical Sciences, 129(S1), e10627. https://doi.org/10.48101/ujms.v129.10627
Issue
Section
Review Articles
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright of their work, with first publication rights granted to Upsala Medical Society. Read the full Copyright- and Licensing Statement.
